Atlas Trials

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

Clinical trial NCT03697252 · COMPLETED

Trial details

NCT number
NCT03697252
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2018-09-18
Primary completion
2019-09-04
Enrollment
182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.